| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-120 |
Sentence |
denotes |
Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam. |
| T1 |
0-120 |
Sentence |
denotes |
Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam. |
| TextSentencer_T2 |
121-132 |
Sentence |
denotes |
BACKGROUND: |
| T2 |
121-132 |
Sentence |
denotes |
BACKGROUND: |
| TextSentencer_T3 |
133-366 |
Sentence |
denotes |
Familial adenomatous polyposis (FAP) is an autosomal, dominantly inherited predisposition to colorectal cancer caused by germline mutations within the adenomatous polyposis coli (APC) gene, a key member of the Wnt signalling pathway. |
| T3 |
133-366 |
Sentence |
denotes |
Familial adenomatous polyposis (FAP) is an autosomal, dominantly inherited predisposition to colorectal cancer caused by germline mutations within the adenomatous polyposis coli (APC) gene, a key member of the Wnt signalling pathway. |
| TextSentencer_T4 |
367-541 |
Sentence |
denotes |
A new class of non-steroidal anti-inflammatory drugs (NSAIDs), the specific cyclooxygenase 2 (COX-2) inhibitors, have recently been applied for the treatment of FAP patients. |
| T4 |
367-541 |
Sentence |
denotes |
A new class of non-steroidal anti-inflammatory drugs (NSAIDs), the specific cyclooxygenase 2 (COX-2) inhibitors, have recently been applied for the treatment of FAP patients. |
| TextSentencer_T5 |
542-563 |
Sentence |
denotes |
PATIENTS AND METHODS: |
| T5 |
542-563 |
Sentence |
denotes |
PATIENTS AND METHODS: |
| TextSentencer_T6 |
564-854 |
Sentence |
denotes |
The expressions of the Wnt members and targets APC, c-myc, cyclin D1 and COX-2, as measured by real-time quantitative RT-PCR, have been evaluated in fresh samples of normal colorectal mucosa and matched adenoma tissue of six unrelated FAP patients before and after treatment with meloxicam. |
| T6 |
564-854 |
Sentence |
denotes |
The expressions of the Wnt members and targets APC, c-myc, cyclin D1 and COX-2, as measured by real-time quantitative RT-PCR, have been evaluated in fresh samples of normal colorectal mucosa and matched adenoma tissue of six unrelated FAP patients before and after treatment with meloxicam. |
| TextSentencer_T7 |
855-863 |
Sentence |
denotes |
RESULTS: |
| T7 |
855-863 |
Sentence |
denotes |
RESULTS: |
| TextSentencer_T8 |
864-954 |
Sentence |
denotes |
A significant up-regulation of COX-2 in adenomas after treatment with meloxicam was found. |
| T8 |
864-954 |
Sentence |
denotes |
A significant up-regulation of COX-2 in adenomas after treatment with meloxicam was found. |
| TextSentencer_T9 |
955-1152 |
Sentence |
denotes |
Furthermore, in adenomas, a down-regulation of APC after treatment and a tight correlation of the expressions of the two Wnt targets, c-myc and cyclin D1, in both stages of treatment were observed. |
| T9 |
955-1152 |
Sentence |
denotes |
Furthermore, in adenomas, a down-regulation of APC after treatment and a tight correlation of the expressions of the two Wnt targets, c-myc and cyclin D1, in both stages of treatment were observed. |
| TextSentencer_T10 |
1153-1164 |
Sentence |
denotes |
CONCLUSION: |
| T10 |
1153-1164 |
Sentence |
denotes |
CONCLUSION: |
| TextSentencer_T11 |
1165-1317 |
Sentence |
denotes |
A feedback loop mediated by the peroxisome proliferator-activated receptor (PPAR) gamma is discussed as being responsible for the up-regulation of COX-2 |
| T11 |
1165-1317 |
Sentence |
denotes |
A feedback loop mediated by the peroxisome proliferator-activated receptor (PPAR) gamma is discussed as being responsible for the up-regulation of COX-2 |
